Celgene-backed Repare Therapeutics secured $82.5m that will support the entry of its first cancer drug into clinical trials.

Repare Therapeutics, a Canada-based cancer therapy developer backed by pharmaceutical firm Celgene, closed an $82.5m series B round on Wednesday led by Cowen Healthcare Investments, part of financial services group Cowen. OrbiMed, Redmile, BVF Partners, Logos Capital, Versant Ventures, MPM Capital, Fonds de solidarit√© FTQ and BDC Capital also contributed to the round, which followed…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.